Abstract:

Objective: Dosetaksel, which is an anti-ineoplastic agent of the Taksan class, is one of the most important chemotherapeutic agents of recent years. Today, the use of classical chemotherapy agents for breast cancer in conjunction with new molecules is trying to identify more effective treatment options. One of these molecules is the analogue of synthetic curcumin, EF24. Our study aimed at determining the effects of dosetaksel alone and after EF24 pre-conditioning, dosetaksel application, cell reproduction in breast cancer MCF-7 cells and on apoptosis. To determine the cell vitality and cytotoxic effects/effects of EF24 and dosetaksel, trials of 3-(4.5-dimetiltiazole-2-yl)-2,5-difenyltetrazole bromide (MTT) and lactate dehydrogenase (LDH) were performed respectively. The proper doses selected as a result of the cell vitality and cytotoxicity test were applied to the cells after the flow cytometry method was performed cell death analysis. In addition, quantitative real-time polymerase chain reaction analysis (qRT-PCR) and expression of cMYC and cFOS genes at mRNA levels were determined. Results: After pre-application of EF24 to MCF-7 cells, dosetaksel application has significantly decreased cell vitality compared to dosetaksel application alone. The apoptotic and necrotic cell ratio was determined by the flow cytometry method. Furthermore, it was found that the EF24 preconduct significantly reduced the mRNA levels of cMYC and cFOS genes compared to the dosetaksal application alone. The result: EF24 pre-application to MCF-7 cells makes the cell more sensitive than dosetaksel alone, suggests that this application can be used in the treatment of breast cancer. However, experimental in vitro and in vivo models are required for more effective use of the drug in breast cancer treatment.

Keywords: